High GPC-1 expression has been shown to correlate with poor prognosis for certain solid tumours including glioblastoma, pancreatic and oesophageal cancer [34, 36, 37]; thus, Miltuximab® theranostics may have utility in other solid tumours. Here, GPC1 is linked to carcinoma of esophagus.